Document Classification

Section Type: METHODS

Text: Eligible patients were randomly assigned (1:1) to receive either mFOLFOX6 plus bevacizumab (on day 1 of each 2-week cycle, 5 mg/kg intravenous infusion of bevacizumab and a simultaneous intravenous infusion of 85 mg/m (2) oxaliplatin, 200 mg/m (2) l-leucovorin, 400 mg/m (2) bolus fluorouracil, and 2400 mg/m (2) infusional fluorouracil) or SOX plus bevacizumab (on day 1 of each 3-week cycle, 75 mg/kg intravenous infusion of bevacizumab and 130 mg/m (2) intravenous infusion of oxaliplatin ; assigned dose of S-1 twice a day from after dinner on day 1 to after breakfast on day 15, followed by 7-day break).